Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

cART and Supportive Care for HIV-Associated Malignancies

  • Ronald T. Mitsuyasu
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_15-1


cART is an abbreviation for combined antiretroviral therapy and generally refers to a three- or four-drug combination regimen of antiretroviral medications, which is considered standard treatment for human immunodeficiency virus-1 (HIV-1) infection. Another name for cART is highly active antiretroviral therapy (HAART). This treatment is important for suppressing HIV-1 replication and has greatly increased the longevity of individuals with this infection. As part of the treatment of malignancies in HIV-infected patients, cART and other supportive measures such as antiemetics, hematopoietic growth factors, blood transfusions, prophylactic and therapeutic antibiotics, antidiarrheal medications, and psychosocial support for each individual undergoing the stressful therapy for these often life-threatening cancers have greatly enhanced both the efficacy and tolerability of these treatments and allowed patients to achieve remissions and/or cure of their cancers.

cART as Treatment...


Acquire Immune Deficiency Syndrome Hematopoietic Growth Factor Myelosuppressive Effect Routine Screening Procedure Reduce Cancer Health Disparity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Barta SK, Lee SY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AMC trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma. Cancer. 2012;118(16):3977–83.PubMedCrossRefPubMedCentralGoogle Scholar
  2. Corona G, Vaccher E, Cattarossi G, Sartor I, Toffoli G. Potential hazard of pharmacokinetic interaction between lopinavir-ritonavir protease inhibitor and irinotecan. AIDS. 2005;19(17):2043–4.PubMedCrossRefGoogle Scholar
  3. Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, William DC, Laubenstein W. Kaposi’s sarcoma in homosexual men – a report of 8 cases. Lancet. 1981;2(8248):688.Google Scholar
  4. Kaplan LD, Kahn JO, Crowe S, et al. Clinical and viral effects of recombinant GM-CSF in patients receiving chemotherapy for HIV-associated non-Hodgkin’s lymphoma: results of a randomized trial. J Clin Oncol. 1994;9(6):929–40.Google Scholar
  5. Kaplan LD, Straus DU, Testa MA, et al. Low-dose compared to high dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with HIV: NIAID ACTG Trial. N Engl J Med. 1997;336(23):1641–8.PubMedCrossRefGoogle Scholar
  6. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin’s lymphoma, AMC Trial 010. Blood. 2005;106(5):1538–43.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt’s lymphoma vs diffuse large cell lymphoma in the pre-HAART and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430–8.PubMedCrossRefGoogle Scholar
  8. Little RF, Yarchoan R, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2000;12(5):438–44.PubMedCrossRefGoogle Scholar
  9. Longo DL, Steis RG, Lane HC, et al. Malignancies in the AIDS patient: Natural history, treatment strategies and preliminary results. Ann NY Acad Sci. 1984;437:421–30.PubMedCrossRefGoogle Scholar
  10. Makinson A, Pujol JL, LeMoing V, Peyriere H, Reynes J. Interactions between cytotoxic chemotherapy and antiretroviral therapy in HIV-infected patients with lung cancer. J Thorac Oncol. 2001;5(4):562–71.CrossRefGoogle Scholar
  11. Moss AR, McCallum G, Volberding PA, Bacchetti P, Dretz S. Mortality associated with mode of presentation in the acquired immunodeficiency syndrome. J Natl Cancer Inst. 1984;23(6):1281–4.Google Scholar
  12. Ratner L, Lee J, Tang S, et al. Chemotherapy for HIV-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19(8):2171–8.PubMedGoogle Scholar
  13. Scadden D, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor as an alternative to dose modification of the combination of zidovudine + interferon alpha in treatment of AIDS-associated Kaposi’s sarcoma. Am J Clin Oncol. 1991;14 Suppl 1:S40–4.PubMedCrossRefGoogle Scholar
  14. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin’s lymphoma. Blood. 2010;115(15):3008–16.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Thiessard F, Morlat P, Marimoutou C, et al. Prognostic factors after non-Hodgkin’s lymphoma in patients infected with HIV: Aquitaine Cohort France: 1980–1997. Cancer. 2000;88(7):1696–702.PubMedCrossRefGoogle Scholar
  16. Ziegler JL, Drew WL, Miner RC, et al. Outbreak of Burkitt’s-like lymphoma in homosexual men. Lancet. 1982;2(8299):631–3.PubMedCrossRefGoogle Scholar
  17. Ziegler JL, Beckstead SA, Volberding PA, et al. Non-Hodgkin lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and acquired immunodeficiency syndrome. N Engl J Med. 1984a;311(9):565–70.PubMedCrossRefGoogle Scholar
  18. Ziegler JL, Bragg K, Abrams D, et al. High-grade non-Hodgkin’s lymphoma in patients with AIDS. Ann NY Acad Sci. 1984b;437:412–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.UCLA Center for Clinical AIDS Research and Education (CARE Center)University of California, Los AngelesLos AngelesUSA